Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2026 07:30 ET | Source: Biogen Inc.

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease...
January 27, 2026 12:30 ET | Source: Custom Market Insights

[Latest] Global Spatial Biology Market Size/Share Worth USD 7.24 Billion by 2035 at a 19.23% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Spatial Biology Market Size, Trends and Insights By Molecular Technology...
January 13, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...
January 09, 2026 16:05 ET | Source: Alumis Inc.

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 08, 2026 01:00 ET | Source: Pharming Group N.V.

Pharming Group reports preliminary 2025 revenues and announces Investor Day

Pharming announced preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026 at 10:00 EST.
January 06, 2026 16:12 ET | Source: Alumis Inc.

Alumis Announces Proposed Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock
January 06, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
December 11, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be...
December 08, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation...